Novartis
NEWS
In addition to patent cases, partnerships and pledging money to global tropical disease efforts, Novartis scored a win on a combo-treatment for solid tumors.
Funding for life sciences companies picked up this week as investors pumped new money into firms developing treatments for spinal muscular atrophy (SMA), immuno-oncology, allergies and rare diseases.
Precision BioSciences and Novartis are teaming up to develop a potential cure for hemoglobinopathies such as sickle cell disease and beta-thalassemia.
Novartis’ win in the patent dispute over its drug, Gilenya, was short-lived after a U.S. appeals court reversed its 2020 ruling vs. HEC Pharm’s attempt to create a generic version.
Decentralized clinical trials may cost more upfront, but can have huge returns on the back end, according to speakers at Informa Connect’s Decentralized Clinical Trials meeting.
It was an extraordinarily busy week for clinical trial news and updates due to several prominent international conferences. Here’s a look at some of the highlights.
Novartis has fallen victim to a cyberattack. The Swiss pharma giant’s data was hijacked by a well-known online extortion ring dubbed Industrial Spy.
Results of a Phase II/III study showed that patients who were given Tafinlar plus Mekinist saw an overall response rate of 47% vs. 11% for those who received standard chemotherapy only.
In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs. ZS Associates’ Maria Whitman provides analyses and tips.
JOBS
IN THE PRESS